Compare
Merck & vs Viatris (MRK vs VTRS)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Merck & (MRK) returned +73.9% and Viatris (VTRS) +85.2%; so far this year the figures are +39.4% and +59.9%.
Merck & is the larger company by market value, about 15.8 times the size of Viatris.
Revenue grew +4.9% at MRK and +4.3% at VTRS over the last year.
MRK yields 2.32%. VTRS yields 2.41%.
Data as of the latest close. Not investment advice.
Relative performance
| MRK | VTRS | |
|---|---|---|
| Price | $146.73 | $19.91 |
| 1-day | -0.14% | +4.96% |
| YTD | +39.40% | +59.92% |
| 1 year | +73.87% | +85.21% |
| 3 years | +42.66% | +123.21% |
| Market cap | $361.7B | $22.8B |
| P/E | 149.7 | — |
| P/S | 5.37 | 1.55 |
| P/B | 8.06 | 1.67 |
| Revenue growth | +4.90% | +4.30% |
| EPS growth | -87.10% | — |
| Gross margin % | 71.8 | 35.4 |
| Net margin % | 3.6 | -23.9 |
| ROE % | 5.5 | -25.7 |
| Debt / equity | 1.20 | 0.97 |
| FCF yield % | 4.1 | 9.2 |
| Dividend yield % | 2.32 | 2.41 |
| Beta | 0.18 | 0.67 |
| RSI (14) | 51.3 | 68.1 |
| Technical rating |